MA51007A - Sels de phosphoramidate diphosphate de nucléosides utilisés en tant que composés anticancéreux - Google Patents

Sels de phosphoramidate diphosphate de nucléosides utilisés en tant que composés anticancéreux

Info

Publication number
MA51007A
MA51007A MA051007A MA51007A MA51007A MA 51007 A MA51007 A MA 51007A MA 051007 A MA051007 A MA 051007A MA 51007 A MA51007 A MA 51007A MA 51007 A MA51007 A MA 51007A
Authority
MA
Morocco
Prior art keywords
phosphoramidate
anticancer compounds
nucleosides used
diphosphate salts
diphosphate
Prior art date
Application number
MA051007A
Other languages
English (en)
Inventor
Hugh Griffith
Fabrizio Pertusati
Michaela Serpi
Magdalena Slusarczyk
Original Assignee
NuCana plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NuCana plc filed Critical NuCana plc
Publication of MA51007A publication Critical patent/MA51007A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • C07H19/20Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/207Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals
    • C07H19/10Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • C07H19/20Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
MA051007A 2017-12-05 2018-12-05 Sels de phosphoramidate diphosphate de nucléosides utilisés en tant que composés anticancéreux MA51007A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1720279.7A GB201720279D0 (en) 2017-12-05 2017-12-05 Anticancer compounds

Publications (1)

Publication Number Publication Date
MA51007A true MA51007A (fr) 2020-10-14

Family

ID=60950385

Family Applications (2)

Application Number Title Priority Date Filing Date
MA051006A MA51006A (fr) 2017-12-05 2018-12-05 Sels de phosphoramidate diphosphate de nucléosides utilisés en tant que composés anticancéreux
MA051007A MA51007A (fr) 2017-12-05 2018-12-05 Sels de phosphoramidate diphosphate de nucléosides utilisés en tant que composés anticancéreux

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA051006A MA51006A (fr) 2017-12-05 2018-12-05 Sels de phosphoramidate diphosphate de nucléosides utilisés en tant que composés anticancéreux

Country Status (22)

Country Link
US (2) US11560400B2 (fr)
EP (2) EP3720864B1 (fr)
JP (1) JP7268819B2 (fr)
KR (1) KR20200092980A (fr)
CN (1) CN111527098A (fr)
AU (1) AU2018379713A1 (fr)
BR (1) BR112020011221A2 (fr)
CA (1) CA3082269A1 (fr)
CL (1) CL2020001479A1 (fr)
DK (1) DK3720864T3 (fr)
EA (1) EA202091218A1 (fr)
ES (1) ES2910165T3 (fr)
GB (1) GB201720279D0 (fr)
HR (1) HRP20220451T1 (fr)
IL (1) IL274808B2 (fr)
MA (2) MA51006A (fr)
MX (1) MX2020005850A (fr)
PH (1) PH12020550728A1 (fr)
PL (1) PL3720864T3 (fr)
PT (1) PT3720864T (fr)
SG (1) SG11202004342TA (fr)
WO (1) WO2019110991A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL291927A (en) 2014-11-28 2022-06-01 NuCana plc Oligonucleotides containing modified nucleosides

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
GB0505781D0 (en) 2005-03-21 2005-04-27 Univ Cardiff Chemical compounds
US20100297079A1 (en) 2009-05-20 2010-11-25 Chimerix, Inc. Compounds, compositions and methods for treating viral infection
GB201016855D0 (en) 2010-10-06 2010-11-17 Nucana Biomed Ltd Chemical compounds
LT3447061T (lt) 2011-03-01 2022-01-25 NuCana plc Farmacinė vaisto forma, apimanti 5-fluor-2'-deoksiuridinofosforamidato darinį, skirtą naudoti vėžio gydymui
WO2014124430A1 (fr) * 2013-02-11 2014-08-14 Emory University Compositions thérapeutiques renfermant des nucléotides et des nucléosides et utilisations associées
SI3043803T1 (sl) 2013-09-11 2022-09-30 Emory University Nukleotidne in nukleozidne sestave in njihova uporaba
CN105646629A (zh) 2014-11-25 2016-06-08 广州市恒诺康医药科技有限公司 L-核苷类化合物及其应用
IL291927A (en) 2014-11-28 2022-06-01 NuCana plc Oligonucleotides containing modified nucleosides
CA2969372C (fr) 2014-12-15 2023-05-16 Emory University Phosphoramidates pour le traitement du virus de l'hepatite b
RS62434B1 (sr) 2014-12-26 2021-11-30 Univ Emory Antivirusni n4-hidroksicitidin derivati
WO2017106710A1 (fr) 2015-12-17 2017-06-22 Emory University Compositions thérapeutiques renfermant des nucléotides et des nucléosides et utilisations associées
US20190085013A1 (en) 2016-03-07 2019-03-21 Emory University Nucleotide and nucleoside therapeutic compositions and uses related thereto
GB201609602D0 (en) 2016-06-01 2016-07-13 Nucuna Biomed Ltd Chemical compounds
GB201609601D0 (en) 2016-06-01 2016-07-13 Nucana Biomed Ltd Phosphoramidate compounds

Also Published As

Publication number Publication date
JP7268819B2 (ja) 2023-05-08
GB201720279D0 (en) 2018-01-17
US20230192750A1 (en) 2023-06-22
BR112020011221A2 (pt) 2020-11-17
CN111527098A (zh) 2020-08-11
MA51006A (fr) 2020-10-14
AU2018379713A1 (en) 2020-07-23
KR20200092980A (ko) 2020-08-04
PH12020550728A1 (en) 2021-02-15
DK3720864T3 (da) 2022-04-11
ES2910165T3 (es) 2022-05-11
PL3720864T3 (pl) 2022-05-02
CA3082269A1 (fr) 2019-06-13
EP3720864A1 (fr) 2020-10-14
EP3720864B1 (fr) 2022-01-05
PT3720864T (pt) 2022-04-06
HRP20220451T1 (hr) 2022-05-27
IL274808B1 (en) 2023-04-01
JP2021505578A (ja) 2021-02-18
CL2020001479A1 (es) 2020-12-18
MX2020005850A (es) 2020-09-07
EP4043471A1 (fr) 2022-08-17
EA202091218A1 (ru) 2020-09-14
IL274808B2 (en) 2023-08-01
US20210171566A1 (en) 2021-06-10
US11560400B2 (en) 2023-01-24
IL274808A (en) 2020-07-30
SG11202004342TA (en) 2020-06-29
WO2019110991A1 (fr) 2019-06-13

Similar Documents

Publication Publication Date Title
CO2017008403A2 (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
FR24C1009I1 (fr) Composés utilisés comme inhibiteurs de kinase
MA49888A (fr) Composés macrocycliques utilisés en tant qu'inhibiteurs de kinase ros1
MA43169A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma
MA47120A (fr) Dérivés pyridine utilisés en tant qu'immunomodulateurs
MA45669A (fr) Composés hétérocycliques utilisés comme immunomodulateurs
CO2018013105A2 (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
MA52119A (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA51438A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1
MA42990A (fr) Composés utiles en tant qu'immunomodulateurs
IL263121B (en) History of nucleoside phosphoramidate as anticancer agents
BR112018009120A8 (pt) métodos de formação de compostos contendo aromáticos
CR20160321A (es) Modulares de tetrahidropiridopirazinas de gpr6
CO2017000337A2 (es) Derivados de bis(aril)catecol como herbicidas
CL2018001672A1 (es) Formulaciones para derivados de fosforamidato de farmacos nucleosidos.
MX2018007782A (es) Forma cristalina de gemcitabina.
MA41424A (fr) Composés vegfa/ang2
MA51007A (fr) Sels de phosphoramidate diphosphate de nucléosides utilisés en tant que composés anticancéreux
MA41174A (fr) Dérivés d'imidazopyridazine utilisés en tant qu'inhibiteurs de pi3kbeta
MA52557A (fr) Composés de 1h-indazole-3-carboxamide utilisés en tant qu'inhibiteurs de la glycogène synthase kinase 3 bêta
MA51339A (fr) Procédé de préparation de composés pyrimidinyl-4-aminopyrazole
MA55512A (fr) Sel de phosphoramidates de triphosphate de nucléotides en tant que composés anticancéreux
MA45787A (fr) Composés de thiazolo-pyridine substitués en tant qu'inhibiteurs de malt1
BR112017018992A2 (pt) processo de preparação de derivados de fenilisoxazolina substituída
MA45392A (fr) Composés hétérocycliques utilisés comme immunomodulateurs